WO2013115740A1 - Combinaison synergique contenant un dérivé de méglitinide et de l'acide lipoïque - Google Patents

Combinaison synergique contenant un dérivé de méglitinide et de l'acide lipoïque Download PDF

Info

Publication number
WO2013115740A1
WO2013115740A1 PCT/TR2013/000049 TR2013000049W WO2013115740A1 WO 2013115740 A1 WO2013115740 A1 WO 2013115740A1 TR 2013000049 W TR2013000049 W TR 2013000049W WO 2013115740 A1 WO2013115740 A1 WO 2013115740A1
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
lipoic acid
agent
meglitinide derivative
pharmaceutical composition
Prior art date
Application number
PCT/TR2013/000049
Other languages
English (en)
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Priority to EP13715475.3A priority Critical patent/EP2809316A1/fr
Publication of WO2013115740A1 publication Critical patent/WO2013115740A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to combinations of meglitinide derivative agents and alpha-lipoic acid, use of these combinations in the treatment of type 2 diabetes and pharmaceutical compositions comprising said combinations.
  • Meglitinide derivative agents also known as glinides, are effective on insulin secretion.
  • Some examples of the agents belonging to this group are nateglinide, repaglinide, mitiglinide.
  • Alpha-lipoic acid is an agent with anti-oxidant effects. According to the studies conducted, it is known that alpha-lipoic acid prevents organ dysfunction and cardiovascular diseases, migraine, age-related cognitive dysfunction, progression of Alzheimer's disease; provides to heal chronic wounds and treat multiple sclerosis.
  • the pharmaceutical composition wherein a meglitinide derivative agent and alpha- lipoic acid are used together or simultaneously presents higher therapeutic benefit compared to the compositions in which these agents are used separately.
  • meglitinide derivative agent refers to agents such as nateglinide, repaglinide, mitiglinide.
  • use of a meglitinide derivative agent and alpha-lipoic acid in combination provides the therapeutic effect to be observed sooner and be stronger compared to use of these active agents alone. A more effective treatment is enabled for patients this way.
  • all these positive effects are present when both active agents are administered in a single dosage form at the same time or in independent dosage forms simultaneously as well as in combinations wherein both active agents are administered sequentially. High therapeutic benefit can also be observed as long-standing therapeutic effect.
  • the present invention relates to pharmaceutical compositions comprising a meglitinide derivative agent and alpha-lipoic acid for sequential use in separate dosage forms, so as to be administered in separate dosage forms simultaneously or in the same dosage form at the same time.
  • the present invention provides a method treating diabetes type 2 by administering effective amounts of a meglitinide derivative agent and alpha-lipoic acid.
  • the meglitinide derivative agent that shall be used in the combinations of the present invention can be selected from a group comprising nateglinide, repaglinide, mitiglinide.
  • the present invention relates to pharmaceutical compositions comprising pharmaceutically effective amounts of a meglitinide derivative agent and alpha-lipoic acid and at least one pharmaceutically acceptable excipient.
  • meglitinide derivative agent and alpha-lipoic acid can be comprised in a single formulation together with at least one excipient while meglitinide derivative agent and alpha-lipoic acid can also be formulated separately with at least one pharmaceutically acceptable excipient.
  • the different formulations obtained separately can be combined in a single dosage form or prepared as separate dosage forms. In the case that the formulations are in separate dosage forms, said dosage forms can be the same or different.
  • the present invention relates to use of the combination of a meglitinide derivative active agent and alpha-lipoic acid according to the present invention for preparation of a medicament that shall be used in combination therapy so as to be administered simultaneously, sequentially or separately in the treatment of type 2 diabetes.
  • the meglitinide derivative agent used in the pharmaceutical compositions of the present invention can be in the form of its pharmaceutically acceptable salts, hydrates, solvates, esters, enantiomers, diastereomers in terms of chemical structure and/or in amorphous, crystalline forms or in the form of any mixture thereof in terms of polymorphic structure or combinations thereof.
  • Alpha-lipoic acid used in the pharmaceutical compositions of the present invention can be in the form of its pharmaceutically acceptable salts, hydrates, solvates, esters, enantiomers, diastereomers and/or in any of polymorphic forms such as amorph, crystal or combinations thereof.
  • the pharmaceutical compositions of the present invention comprising a meglitinide derivative agent and alpha-lipoic acid can be prepared in any of the dosage forms such as tablet, effervescent tablet, effervescent granule, effervescent dry powder, film-coated tablet, enterically coated tablet, dry powder, granule, capsule, prolonged-release tablet, modified-release tablet, delayed-release tablet, orodispersible tablet, chewing tablet.
  • compositions comprising a meglitinide derivative agent and alpha-lipoic acid can be together in any of these dosage forms while in the case that the meglitinide derivative agent and alpha-lipoic acid are stored in separate dosage forms, said formulations can also be in the form of any of these dosage forms.
  • compositions comprising the combination of the present invention can be in the form of any abovementioned dosage form or in the form of a combination of these dosage forms or in the form of a treatment pack comprising this combination.
  • the pharmaceutical compositions of the present invention comprising a meglitinide derivative agent and alpha-lipoic acid are preferably in film tablet or effervescent tablet or prolonged-release tablet form.
  • composition of the present invention comprising a meglitinide derivative agent and alpha-lipoic acid can comprise various excipients in addition to the meglitinide derivative agent and alpha-lipoic acid.
  • the disintegrant that can be used in the pharmaceutical compositions of the present invention can be selected from a group comprising carboxymethyl cellulose, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, microcrystalline cellulose, methyl cellulose, chitosan, starch, sodium starch glycolate.
  • the diluent that can be used in the pharmaceutical compositions of the present invention can be selected from a group comprising calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, microcrystalline cellulose, dextrose, fructose, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrin, maltose, mannitol, simethicone, sorbitol, starch, sodium chloride, sucrose, talc, xylitol.
  • the lubricant that can be used in the pharmaceutical compositions of the present invention can be selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, sodium benzoate, potassium benzoate, sodium lauryl sulphate, talc, stearic acid, zinc stearate.
  • the glidant that can be used in the pharmaceutical compositions of the present invention can be selected from a group comprising tribasic calcium phosphate, colloidal silicone dioxide, magnesium silicate, magnesium trisilicate, talc.
  • the binder that can be used in the pharmaceutical compositions of the present invention can be selected from a group comprising carboxymethyl cellulose sodium, ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminium silicate, maltodextrin, methyl cellulose, povidone, starch.
  • the acidic agent composing the effervescent couple comprising at least one acidic agent and at least one basic agent that can be used in the pharmaceutical compositions of the present invention can be selected from a group comprising organic acids such as malic acid, citric acid, tartaric acid, fumaric acid; and the basic agent can be selected from a group comprising agents such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate.
  • the pH regulating agent that can be used in the pharmaceutical compositions of the present invention can be selected from citrate, phosphate, carbonate, tartrate, fumarate, acetate and amino acid salts.
  • the surfactant that can be used in the pharmaceutical compositions of the present invention can be selected from sodium lauryl sulphate, polysorbate, polyoxyethylene, polyoxypropylene glycol and similar agents.
  • the stabilizing agent that can be used in the pharmaceutical compositions of the present invention can be selected from a group comprising tocopherol, tetrasodium edetate, nicotinamide, cyclodextrin.
  • the sweetener and/or taste regulating agent that can be used in the pharmaceutical compositions of the present invention can be selected from a group comprising acesulfame, aspartame, dextrose, fructose, maltitol, maltose, mannitol, saccharine, saccharine sodium, sodium cyclamate, sorbitol, sucralose, sucrose, xylitol, sodium chloride.
  • the flavoring agent that can be used in the pharmaceutical compositions of the present invention can be selected from a group comprising menthol, lemon, orange, vanilla, berry, raspberry, caramel and similar flavors.
  • compositions of the present invention comprise a meglitinide derivative agent in the range of 0.1% to 99% by weight, preferably in the range of 1% to 98% by weight, more preferably in the range of 5% to 95% by weight, for instance in the range of 5, 10, 15, 20, 25, 30% to 35, 40, 45, 50, 55, 60, 65, 70, 80, 90% by weight.
  • compositions of the present invention comprise alpha-lipoic acid in the range of 0.1% to 99% by weight, preferably in the range of 1% to 98% by weight, more preferably in the range of 5% to 95% by weight, for instance in the range of 5, 10, 15, 20, 25, 30% to 35, 40, 45, 50, 55, 60, 65, 70, 80, 90% by weight.
  • compositions of the present invention comprise a meglitinide derivative agent in the range of 0.01 mg to 500 mg, preferably in the range of 0.1 mg to 300 mg, more preferably in the range of 0.5 mg to 250 mg.
  • the pharmaceutical compositions of the present invention comprise alpha-lipoic acid in the range of 100 mg to 1500 mg, preferably in the range of 150 mg to 1200 mg, more preferably in the range of 200 mg to 1000 mg.
  • compositions of the present invention comprising a meglitinide derivative agent and alpha-lipoic acid can optionally comprise a third active agent in addition to the meglitinide derivative agent and alpha-lipoic acid.
  • the third active agent can be selected from antacid, anticholinergic, antispasmodic, antiemetic, antibiotic, antipropulsive, antiallergic, antidiarrheal, antiobesity, antithrombotic, antifibrinolytic, antianemic, antihypertensive, antifungal, antipruritic, antipsoriatic, antibiotic, antiseptic, antiacne, antibacterial, antimycotic, antiviral, antineoplastic, antiarrhythmic, antiadrenergic, antiepileptic, anti-parkinson, antiprotozoal, anthelmintic, antiinflammatory, diuretic, laxative, sulphonamide, imidazole, corticosteroid, thiazolidinedione, big
  • compositions of the present invention comprising a meglitinide derivative agent and alpha-lipoic acid
  • a third active agent in addition to these two agents, preferably an anti-diabetic agent; meglitinide, thiazolidinedione, sulfonylurea, peptide analogue, biguanide, organosulfur compound, more preferably an agent selected from a group comprising voglibose, acarbose, miglitol, nateglinide, repaglinide, rosiglitazone, pioglitazone, rivoglitazone, troglitazone, rosiglitazone maleate, pioglitazone hydrochloride, tolbutamide, acetohexamide, glibenclamide, chlorpropamide, carbutamide, glibornuride, glipizide, gliquidone, glyburide, glimepiride, gli
  • composition of the present invention can be obtained by a method comprising the steps of;
  • the pharmaceutical composition or compositions obtained can be formed into any of the abovementioned dosage forms.
  • the tablets obtained can be treated with film coating agents, for instance with sugar-based coating agents, water soluble film coating agents, enteric coating agents, delayed-release coating agents or with coating compositions comprising any combination thereof.
  • Saccharose can be used singly or optionally with any of the agents such as talc, calcium carbonate, calcium phosphate, calcium sulphate, gelatine, gum arabic, polyvinylpyrrolidone and pullulan or a combination thereof as the sugar based coating agent.
  • agents such as talc, calcium carbonate, calcium phosphate, calcium sulphate, gelatine, gum arabic, polyvinylpyrrolidone and pullulan or a combination thereof as the sugar based coating agent.
  • the water soluble film coating agent can be selected from cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methyl hydroxyethyl cellulose and sodium carboxymethyl cellulose; synthetic polymers such as polyvinyl acetal diethyl aminoacetate, aminoalkyl methacrylate copolymers and polyvinylpyrrolidone and polysaccharides such as pullulan or combinations thereof.
  • cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methyl hydroxyethyl cellulose and sodium carboxymethyl cellulose
  • synthetic polymers such as polyvinyl acetal diethyl aminoacetate, aminoalkyl methacrylate copolymers and polyvinylpyrrolidone and polysaccharides such as pullulan or combinations thereof.
  • the enteric coating agents can be selected from cellulose derivatives such as hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethyl cellulose, cellulose acetate phthalate; acrylic acid derivatives such as methacrylic acid copolymer L, methacrylic acid copolymer LD and methacrylic acid copolymer S and natural substances such as shellac or combinations thereof.
  • cellulose derivatives such as hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethyl cellulose, cellulose acetate phthalate
  • acrylic acid derivatives such as methacrylic acid copolymer L, methacrylic acid copolymer LD and methacrylic acid copolymer S and natural substances such as shellac or combinations thereof.
  • the delayed release coating agents can be selected from cellulose derivatives such as ethyl cellulose; acrylic acid derivatives such as aminoalkyl methacrylate copolymer RS, emulsion copolymer of ethyl acrylate-methyl methacrylate or combinations thereof.
  • the pharmaceutical composition of the present invention can be used in the prophylaxis and treatment of type 2 diabetes.
  • Dio value of the meglitinide derivative agent (for instance; nateglinide, repaglinide, mitiglinide) in the pharmaceutical compositions of the present invention is in the range of 0.1 ⁇ to 50 ⁇ , preferably in the range of 1 ⁇ to 30 ⁇ ;
  • d 10 value of alpha-lipoic acid is in the range of 0.1 ⁇ to 80 ⁇ , preferably in the range of 1 ⁇ to 50 ⁇ .
  • EXAMPLE 1 Pharmaceutical compositions comprising nateglinide and alpha-lipoic acid combination
  • Nateglinide and alpha-lipoic acid are granulated.
  • the granules obtained are dried and then mixed with the other excipients.
  • Lubricant is added to the obtained mixture and the final mixture is compressed in tablet compression machine.
  • the tablets are coated with release regulating agent and dried.
  • EXAMPLE 2 Pharmaceutical compositions comprising repaglinide and alpha lipoic acid combination
  • Repaglinide and some part of the other excipients are mixed and subjected to wet-granulation process with the granulation solution.
  • the granules are dried and mixed with the rest of the excipients and alpha-lipoic acid.
  • the homogenous mixture obtained is mixed with the lubricant and compressed in tablet form in the tablet compression machine.
  • EXAMPLE 3 Film tablet formulation comprising mitiglinide and alpha-lipoic acid combination
  • Mitiglinide and the other excipients are mixed and granulated.
  • the obtained granules are added to alpha-lipoic acid and the lubricant.
  • the final mixture is compressed in tablet form and coated with the coating agent and then dried.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un procédé utilisé pour la préparation de formulations pharmaceutiques contenant un agent dérivé du méglitinide, et de l'acide alpha-lipoïque, qui sont destinées au traitement du diabète de type 2.
PCT/TR2013/000049 2012-01-31 2013-01-31 Combinaison synergique contenant un dérivé de méglitinide et de l'acide lipoïque WO2013115740A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13715475.3A EP2809316A1 (fr) 2012-01-31 2013-01-31 Combinaison synergique contenant un dérivé de méglitinide et de l'acide lipoïque

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201201096 2012-01-31
TR2012/01096 2012-01-31

Publications (1)

Publication Number Publication Date
WO2013115740A1 true WO2013115740A1 (fr) 2013-08-08

Family

ID=48083587

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/TR2013/000049 WO2013115740A1 (fr) 2012-01-31 2013-01-31 Combinaison synergique contenant un dérivé de méglitinide et de l'acide lipoïque
PCT/TR2013/000048 WO2013115739A1 (fr) 2012-01-31 2013-01-31 Procédé de préparation de formulations contenant du natéglinide et de l'acide lipoïque

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/TR2013/000048 WO2013115739A1 (fr) 2012-01-31 2013-01-31 Procédé de préparation de formulations contenant du natéglinide et de l'acide lipoïque

Country Status (2)

Country Link
EP (1) EP2809316A1 (fr)
WO (2) WO2013115740A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015065521A1 (fr) * 2012-11-05 2015-05-07 Tibbs Kenneth John Préparation pharmaceutique et procédé pour le traitement du diabète
CN109864974A (zh) * 2017-12-01 2019-06-11 王辉 马来酸罗格列酮分散片及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021005888A (es) 2018-11-26 2021-06-23 Procter & Gamble Preparacion farmaceutica solida que contiene acido lipoico y uso de esta.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312924A (en) * 1983-12-30 1994-05-17 Dr. Karl Thomae Gmbh Phenylacetic acid benzylamides
WO2002072146A2 (fr) * 2001-03-12 2002-09-19 Novartis Ag Combinaison de composes organiques
EP1283054A1 (fr) * 2000-03-17 2003-02-12 Ajinomoto Co., Inc. Medicaments permettant de traiter les complications du diabete et des neuropathies et utilisation de ces medicaments
WO2009085223A1 (fr) * 2007-12-20 2009-07-09 Indigene Pharmaceuticals, Inc. Combinaison de r-(+)-lipoate de metformine et d'agents antihyperglycémiques pour le traitement de l'hyperglycémie diabétique et des complications diabétiques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03169813A (ja) * 1989-11-09 1991-07-23 Asta Pharma Ag 細胞保護作用を有する疼痛及び炎症性疾患及び／又はレトロウイルスに起因する病気の治療用医薬並びにその製法
WO2002040010A1 (fr) * 2000-10-24 2002-05-23 Ajinomoto Co.,Inc. Preparations de medicament contenant du nateglinide
KR20080083071A (ko) * 2003-08-08 2008-09-12 아지노모토 가부시키가이샤 나테글리니드 함유 제제
WO2005020979A1 (fr) * 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited Procede de preparation de compositions pharmaceutiques a base de nateglinide
IT1399923B1 (it) * 2010-05-11 2013-05-09 Cbb Net S A Procedimento di preparazione di sali dell'acido (r) alfa-lipoico loro formulazione ed uso nelle composizioni farmaceutiche in forma di compresse che li contengono

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312924A (en) * 1983-12-30 1994-05-17 Dr. Karl Thomae Gmbh Phenylacetic acid benzylamides
EP1283054A1 (fr) * 2000-03-17 2003-02-12 Ajinomoto Co., Inc. Medicaments permettant de traiter les complications du diabete et des neuropathies et utilisation de ces medicaments
WO2002072146A2 (fr) * 2001-03-12 2002-09-19 Novartis Ag Combinaison de composes organiques
WO2009085223A1 (fr) * 2007-12-20 2009-07-09 Indigene Pharmaceuticals, Inc. Combinaison de r-(+)-lipoate de metformine et d'agents antihyperglycémiques pour le traitement de l'hyperglycémie diabétique et des complications diabétiques

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KANDEIL M A ET AL: "Role of lipoic acid on insulin resistance and leptin in experimentally diabetic rats", JOURNAL OF DIABETES AND ITS COMPLICATIONS, ELSEVIER SCIENCE, NEW YORK, NY, US, vol. 25, no. 1, 1 January 2011 (2011-01-01), pages 31 - 38, XP027554187, ISSN: 1056-8727, [retrieved on 20091029] *
POH Z X ET AL: "A Current Update on the Use of Alpha Lipoic Acid in the Management of Type 2 Diabetes Mellitus", ENDOCRINE, METABOLIC & IMMUNE DISORDERS - DRUG TARGETS, BENTHAM SCIENCE PUBLISHERS LTD, BUSSUM, NL, vol. 9, no. 4, 1 December 2009 (2009-12-01), pages 392 - 398, XP009170039, ISSN: 1871-5303 *
SINGH U ET AL: "Alpha-lipoic acid supplementation and diabetes", NUTRITION REVIEWS, ALLEN PRESS, LAWRENCE, KS, US, vol. 66, no. 11, 1 November 2008 (2008-11-01), pages 646 - 657, XP002551024, ISSN: 0029-6643, [retrieved on 20081027], DOI: 10.1111/J.1753-4887.2008.00118.X *
SONG K-H ET AL: "alpha-Lipoic acid prevents diabetes mellitus in diabetes-prone obese rats", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 326, no. 1, 31 December 2004 (2004-12-31), pages 197 - 202, XP004672568, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2004.10.213 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015065521A1 (fr) * 2012-11-05 2015-05-07 Tibbs Kenneth John Préparation pharmaceutique et procédé pour le traitement du diabète
CN109864974A (zh) * 2017-12-01 2019-06-11 王辉 马来酸罗格列酮分散片及其制备方法

Also Published As

Publication number Publication date
WO2013115739A1 (fr) 2013-08-08
EP2809316A1 (fr) 2014-12-10

Similar Documents

Publication Publication Date Title
KR102479497B1 (ko) 바레니클린 서방성 제제 및 이의 제조 방법
JP7444967B2 (ja) ４－アミノ－３－置換ブタン酸誘導体の安定化製剤
WO2019194773A2 (fr) Combinaison contenant de la linagliptine et de la metformine
ES2555927T3 (es) Composiciones de liberación modificada de epalrestat o un derivado del mismo y métodos para el uso de las mismas
EP3976014A1 (fr) Combinaison comprenant de l'alogliptine et de la metformine
WO2013115740A1 (fr) Combinaison synergique contenant un dérivé de méglitinide et de l'acide lipoïque
WO2013115744A1 (fr) Procédé de préparation de compositions pharmaceutiques (effervescentes) contenant un inhibiteur de l'apha-glucosidase (p. ex. voglibose et metformine)
EP3784672A2 (fr) Formulations de comprimés comprenant de la metformine et de la sitagliptine
WO2013095316A1 (fr) Combinaison synergique comprenant un agent anti-diabétique
WO2013077824A1 (fr) Procédé de fabrication d'une préparation comprenant de la metformine
ES2435966T3 (es) Combinaciones de vildagliptina y glimepirida
WO2013109227A1 (fr) Compositions pharmaceutiques contenant du ceftibutène
WO2013115738A1 (fr) Acarbose micronisée
WO2019162800A1 (fr) Composition pharmaceutique comprenant de la remogliflozine et un agent antidiabétique
WO2013077819A1 (fr) Préparations pharmaceutiques comprenant du natéglinide
WO2018185669A1 (fr) Compositions effervescentes comprenant de la saxagliptine ou un sel de celle-ci
EP4008316A1 (fr) Formulation de comprimé revêtu de film comprenant de la dapagliflozine et du chlorhydrate de metformine
WO2014104989A1 (fr) Compositions pharmaceutiques comprenant de l'aripiprazole
WO2013077822A1 (fr) Nouvelles préparations pour le traitement du diabète
WO2013074049A1 (fr) Metformine micronisée
WO2013077825A1 (fr) Procédé de fabrication d'une préparation comprenant de la metformine
WO2019132833A1 (fr) Combinaison à libération modifiée comprenant de la linagliptine et de la metformine
WO2019145926A1 (fr) Formulations pharmaceutiques stables contenant de la thiamine
WO2019212427A2 (fr) Compositions comprenant de l'erdostéine et de l'acide ascorbique
WO2013115741A1 (fr) Compositions pharmaceutiques contenant un inhibiteur de l'alpha-glucosidase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13715475

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2013715475

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013715475

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE